In 1991, graduate student Simon Friedman was studying drug design at the University of California in San Francisco. One day, he was chatting with Diana Roe, a fellow student, about one of the field’s latest rages–HIV protease inhibitors designed to combat the AIDS virus–and the discussion turned to unexpected new therapies that might come from medicinal chemists.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.